目的： 探讨γδT细胞联合半乳糖凝集素1（galectin-1，Gal-1）单抗对人宫颈癌细胞的杀伤作用。 方法： 从人宫颈癌组织中分离肿瘤浸润淋巴细胞（tumor infiltrating lymphocytes，TILs），并通过固相单抗包被法在体外扩增获得γδT细胞，流式细胞术检测其纯度；Western blotting和ELISA法检测宫颈癌SiHa、HeLa细胞及其上清中Gal-1的表达，乳酸脱氢酶（lactate dehydrogenase，LDH）释放实验检测γδT细胞联合Gal-1单抗对宫颈癌SiHa、HeLa细胞的杀伤作用。皮下注射SiHa细胞制备荷瘤小鼠模型，随机分为对照组、同型对照组（IgG1组）、γδT细胞组（γδT组）、Gal-1单抗组（Gal-1mAb组）及γδT细胞联合Gal-1单抗组（γδT+Gal-1 mAb组），观察各组荷瘤小鼠移植瘤生长的情况。 结果： 固相单抗包被法体外扩增后TCRγδ阳性γδT细胞比例达（91.2±1.2）%，SiHa、HeLa细胞及其上清中Gal-1高表达。与对照组相比，Gal-1 mAb组能够增强γδT细胞体外杀伤SiHa细胞\[（68.1±3.0）% vs （48.7±3.8）%，P<0.05\]和HeLa细胞\[（79.4±5.6）% vs （ 48.3±6.5）%，P<0.05\]的效率。裸鼠荷瘤30 d，γδT+Gal-1 mAb组的移植瘤体积明显小于Gal-1单抗组\[（31.3±9.1） vs （199.6±41.2）mm3，P<0.01\]和γδT细胞组\[（31.3±9.1） vs （85.6±45.1）mm3，P<0.05\]。 结论： Gal-1单抗能增强γδT细胞对宫颈癌细胞的杀伤作用。

Objective:To investigate the cytotoxicity of γδT cells combined with galectin-1 (Gal-1) monoclonal antibody against human cervical carcinoma cells. Methods: γδT cells were expanded in vitro using the solid-phase antibody coated method from tumor infiltrating lymphocyte (TILs) of the human cervical cancer specimens. The purity of γδT cells was measured by flow cytometry. The expressions of Gal-1 in cervical carcinoma SiHa and HeLa cells and in cell supernatants were detected by Western blotting and ELISA, respectively. The cytotoxicity of γδT cells combined with Gal-1 mAb against the human cervical cancer SiHa and HeLa cells was measured by lactate dehydrogenase (LDH) release assay. Tumor-bearing mouse model was established by subcutaneous injection of SiHa cells. Tumor-bearing mice were randomly divided into a control group (SiHa group), an isotype control group (SiHa+mouse IgG1 group), a γδT cell group (SiHa+γδT group), a Gal-1 mAb group (SiHa+γδT+Gal-1 mAb group) and a γδT cell + Gal-1 mAb group (γδT cell+Gal-1 mAb group). The tumor growth was observed in different groups. Results: The percentage of TCRγδ positive T cells expanded using the solid-phase antibody coated method in vitro was (91.2±1.2) %. Gal-1 was over-expressed in SiHa, HeLa cells and cell supernatants. Compared with the control group, the Gal-1 mAb group showed an increasing cytotoxicity efficiency on SiHa cells (\[68.1±3.0\] % vs \[48.7±3.8\]%, P<005) and HeLa cells (\[79.4±5.6\]% vs \[48.3±6.5\]%, P<0.05). The volume of implanted tumors in the γδT +Gal-1 mAb group was significantly smaller than that in the Gal-1 mAb group (\[31.3±9.1\] vs \[199.6±41.2\] mm3, P<0.01) and the γδT cell group (\[31.3±9.1\] vs \[85.6±45.1\] mm3, P<0.05) 30 days after tumor implantation in nude mice. Conclusion: Gal-1 mAb antibody can boost up the cytotoxicity of γδT cells against the human cervical carcinoma cells.

湖北省杰出青年基金资助项目资助（No. 2008CDB126）； 武汉科技大学人才启动项目资助（No. 530033）